222 related articles for article (PubMed ID: 9210876)
1. A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters.
McKeever PE; Ross DA; Strawderman MS; Brunberg JA; Greenberg HS; Junck L
J Neuropathol Exp Neurol; 1997 Jul; 56(7):798-805. PubMed ID: 9210876
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas.
Wakimoto H; Aoyagi M; Nakayama T; Nagashima G; Yamamoto S; Tamaki M; Hirakawa K
Cancer; 1996 Jan; 77(2):373-80. PubMed ID: 8625247
[TBL] [Abstract][Full Text] [Related]
3. MIB-1 labeling index in astrocytic tumors--a clinicopathologic study.
Neder L; Colli BO; Machado HR; Carlotti CG; Santos AC; Chimelli L
Clin Neuropathol; 2004; 23(6):262-70. PubMed ID: 15584210
[TBL] [Abstract][Full Text] [Related]
4. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.
Cheville JC; Zincke H; Lohse CM; Sebo TJ; Riehle D; Weaver AL; Blute ML
Cancer; 2002 Apr; 94(8):2180-4. PubMed ID: 12001115
[TBL] [Abstract][Full Text] [Related]
5. Final report on the University of California-San Francisco experience with bromodeoxyuridine labeling index as a prognostic factor for the survival of glioma patients.
Lamborn KR; Prados MD; Kaplan SB; Davis RL
Cancer; 1999 Feb; 85(4):925-35. PubMed ID: 10091772
[TBL] [Abstract][Full Text] [Related]
6. Use of proliferative markers Ki-67 (MIB-1) and proliferating cell nuclear antigen (PC10) in transitional cell carcinoma of the renal pelvis.
Cheville JC; Terrell RB; Cohen MB
Mod Pathol; 1994 Sep; 7(7):794-800. PubMed ID: 7824516
[TBL] [Abstract][Full Text] [Related]
7. Proliferation index as a predictor of prognosis in malignant gliomas of childhood.
Pollack IF; Campbell JW; Hamilton RL; Martinez AJ; Bozik ME
Cancer; 1997 Feb; 79(4):849-56. PubMed ID: 9024724
[TBL] [Abstract][Full Text] [Related]
8. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
Saeger W; Lüdecke B; Lüdecke DK
Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
[TBL] [Abstract][Full Text] [Related]
9. Prognostic relevance of MIB-1 immunoreactivity, S-phase fraction, 5-bromo-2'-deoxyuridine labeling indices, and mitotic figures in gliomas.
Struikmans H; Rutgers DH; Jansen GH; Dullens HF; Oosten L; Tulleken CA; van der Tweel I; Battermann JJ
Radiat Oncol Investig; 1999; 7(4):243-8. PubMed ID: 10492165
[TBL] [Abstract][Full Text] [Related]
10. Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value.
Spyratos F; Ferrero-Poüs M; Trassard M; Hacène K; Phillips E; Tubiana-Hulin M; Le Doussal V
Cancer; 2002 Apr; 94(8):2151-9. PubMed ID: 12001111
[TBL] [Abstract][Full Text] [Related]
11. Prognostic implication of proliferative markers MIB-1 and PC10 in esophageal squamous cell carcinoma.
Lam KY; Law SY; So MK; Fok M; Ma LT; Wong J
Cancer; 1996 Jan; 77(1):7-13. PubMed ID: 8630942
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic study of forty-four histologically pure supratentorial oligodendrogliomas.
Prayson RA; Mohan DS; Song P; Suh JH
Ann Diagn Pathol; 2000 Aug; 4(4):218-27. PubMed ID: 10982299
[TBL] [Abstract][Full Text] [Related]
13. Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples.
Sallinen PK; Haapasalo HK; Visakorpi T; Helén PT; Rantala IS; Isola JJ; Helin HJ
J Pathol; 1994 Dec; 174(4):275-82. PubMed ID: 7884589
[TBL] [Abstract][Full Text] [Related]
14. Correlation of bcl-2, p53, and MIB-1 expression with ependymoma grade and subtype.
Rushing EJ; Brown DF; Hladik CL; Risser RC; Mickey BE; White CL
Mod Pathol; 1998 May; 11(5):464-70. PubMed ID: 9619600
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas.
Kros JM; Hop WC; Godschalk JJ; Krishnadath KK
Cancer; 1996 Sep; 78(5):1107-13. PubMed ID: 8780550
[TBL] [Abstract][Full Text] [Related]
16. Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas.
Kurt E; Zheng PP; Hop WC; van der Weiden M; Bol M; van den Bent MJ; Avezaat CJ; Kros JM
Cancer; 2006 Jan; 106(2):388-95. PubMed ID: 16342252
[TBL] [Abstract][Full Text] [Related]
17. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma.
Oyama T; Osaki T; Nose N; Ichiki Y; Inoue M; Imoto H; Yoshimatsu T; Kodate M; Uramoto H; Mizoue T; Yano K; Yasumoto K
Anticancer Res; 2000; 20(1B):505-10. PubMed ID: 10769714
[TBL] [Abstract][Full Text] [Related]
18. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
19. Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas.
Onda K; Davis RL; Shibuya M; Wilson CB; Hoshino T
Cancer; 1994 Oct; 74(7):1921-6. PubMed ID: 7521787
[TBL] [Abstract][Full Text] [Related]
20. Subependymal giant cell astrocytoma: a clinicopathological study of 23 cases with special emphasis on proliferative markers and expression of p53 and retinoblastoma gene proteins.
Sharma M; Ralte A; Arora R; Santosh V; Shankar SK; Sarkar C
Pathology; 2004 Apr; 36(2):139-44. PubMed ID: 15203749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]